Jiangxi Qingfeng Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JIANGXI QINGFENG, and what generic and branded alternatives to JIANGXI QINGFENG drugs are available?
JIANGXI QINGFENG has one approved drug.
Summary for Jiangxi Qingfeng
| US Patents: | 0 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Jiangxi Qingfeng
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangxi Qingfeng | ERIBULIN MESYLATE | eribulin mesylate | SOLUTION;INTRAVENOUS | 218281-001 | Jun 28, 2024 | AP | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
